15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006 Download PDF Post navigationPreviousPrevious post:AB Science webcast – Masitinib in Sickle Cell DiseaseNextNext post:AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyRelated PostsA new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024
A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patientsMay 7, 2024
The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB ScienceMay 2, 2024
AB Science announces a slight delay in the publication of its 2023 annual financial reportApril 30, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024
Summary of the live webcast held on March 4, 2024, providing an update on AB Science developmentMarch 7, 2024
